CD70-Binding Antibody Variable Region Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD70 antibodies are insufficient in effectively blocking CD70-CD27 interactions and inducing cytotoxicity against CD70-expressing tumor cells, necessitating the development of antibodies with superior binding capabilities and immune activation mechanisms.
Innovation Solution
A novel monoclonal antibody or antigen binding portion that binds CD70, blocking CD70-CD27 interactions and inducing antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity, with a heavy chain variable region and light chain variable region comprising specific amino acid sequences for enhanced activity, potentially surpassing the efficacy of existing antibodies like cusatuzumab.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-CD70 antibodies are used, then CD70-CD27 interactions can be blocked to some extent, but the blocking capability and cytotoxicity induction are insufficient
Solution Approach 1:
The patent modifies the amino acid sequences in the variable regions of the antibody (both heavy and light chains) to optimize binding affinity and biological activity. Specific amino acid substitutions in the CDR regions enhance the antibody's ability to block CD70-CD27 interactions and induce cytotoxicity, directly addressing the insufficiency of current antibodies.
Solution Approach 2:
The patent creates a chimeric antibody structure combining mouse variable regions (for antigen binding) with human constant regions (for reduced immunogenicity and enhanced effector function). This composite structure integrates the high affinity of mouse antibodies with the superior in vivo performance of human antibodies, improving both blocking capability and cytotoxicity induction.
2Reliability
If existing anti-CD70 antibodies like cusatuzumab are used, then some anti-tumor effects are achieved, but superior binding capabilities and immune activation are not attained
Solution Approach 1:
The patent systematically optimizes amino acid parameters in the variable regions through sequence modifications. The heavy chain variable region and light chain variable region contain specific amino acid substitutions that enhance binding affinity to CD70 and improve immune activation, achieving superior anti-tumor efficacy compared to existing antibodies.
Solution Approach 2:
The patent divides the antibody into distinct functional segments: mouse-derived variable regions for antigen recognition and binding, and human-derived constant regions for effector functions and reduced immunogenicity. This segmentation allows independent optimization of each region's properties to achieve overall superior performance.
Data Source
Figure 1
Figure 2A~2B
Figure 2C~2D
AI summary
Disclosed is an antibody that specifically binds CD70, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD70 signaling using the antibody or antigen binding portion thereof are also provided.